The Profile of Osteogenesis Imperfecta in Dr. Moewardi General Hospital Year 2020-2021: A Retrospective Study


  • Udi Heru Nefihancoro Department of Orthopaedic and Traumatology Faculty of Medicine Universitas Sebelas Maret
  • Ricat Hinaywan Malik Department of Orthopaedic and Traumatology Faculty of Medicine Universitas Sebelas Maret



Bisphosphonate, epidemiology, osteogenesis imperfecta, signs, surgery, symptoms


Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by bone fragility and long bone deformities. This study aims to report the profile of osteogenesis imperfecta in Dr. Moewardi General Hospital. The patients were searched from the medical record, registered from January 1, 2020, to December 31, 2021, in Dr. Moewardi General Hospital, a tertiary hospital in Surakarta, Indonesia. The data were recorded and described in tables as age, sex, type of OI according to Sillence, clinic, ward admission, signs and symptoms, bisphosphonate therapy and its discipline, as well as the surgical/non-surgical treatment. The quantity of male patients is higher than that of females, OI type IV is the most common, the most common sign/symptoms are fracture and blue sclera, and the most common bone to be fractured is the femur. More than half of patients received bisphosphonate therapy, but only a quarter received it routinely. More than half of patients have performed surgery as the treatment of fractures. Osteogenesis imperfecta patients require an interdisciplinary and tailored treatment that involves both medical and surgical components.


Download data is not yet available.


Burtsev ME, Frolov AV, Logvinov AN, Ilyin DO, and Korolev AV. Current Approach to Diagnosis and Treatment of Children with Osteogenesis Imperfecta. Pediatric Traumatology, Orthopaedics, and Reconstructive Surgery. 2019; 7(2): 87-102.

Lim J, Grafe I, Alexander S, and Lee B. Genetic Causes and Mechanisms of Osteogenesis Imperfecta. Bone. 2017; 102: 40-49.

Folkestad L, Hald JD, Ersbøll AK, et al. Fracture Rates and Fracture Sites in Patients with Osteogenesis Imperfecta: A Nationwide Register-Based Cohort Study. Journal of Bone and Mineral Research. 2017; 32(1): 125-134.

Sillence DO, Senn A, and Danks DM. Genetic Heterogeneity in Osteogenesis Imperfecta. Journal of Medical Genetics. 1979; 16(2): 101-116.

Marini JC, Forlino A, Bachinger HP. Osteogenesis Imperfecta. Nature Reviews Disease Primers. 2017; 3: 17052.

Ignatovich ON, Namazova-Baranova LS, Margieva TV, et al. Osteogenesis Imperfecta: Diagnostic Feature. Pediatric Pharmacology. 2018; 15(3): 224-232.

Lindahl K, Astrom E, Rubin CJ, et al. Genetic Epidemiology, Prevalence, and Genotype–Phenotype Correlations in the Swedish Population with Osteogenesis Imperfecta. European Journal of Human Genetics. 2015; 23(8): 1042-1050.

Martin E and Shapiro JR. Osteogenesis Imperfecta: Epidemiology and Pathophysiology. Current Osteoporosis Reports. 2007; 5(3): 91-97.

Etich J, Leßmeier L, Rehberg M, et al. Osteogenesis Imperfecta—Pathophysiology and Therapeutic Options. Molecular and Cellular Pediatrics. 2020; 7: 1-9.

Zhytnik L, Maasalu K, Duy BH, et al. IFITM5 Pathogenic Variant Causes Osteogenesis Imperfecta V with Various Phenotype Severity in Ukrainian and Vietnamese Patients. Human Genomics. 2019; 13: 1-11.

Goudriaan WA, Harsevoort GJ, van Leeuwen M, Franken AA, and Janus GJM. Incidence and Treatment of Femur Fractures in Adults with Osteogenesis Imperfecta: An Analysis of an Expert Clinic of 216 Patients. European Journal of Trauma and Emergency Surgery. 2020; 46(1): 165-171.

Storoni S, Treurniet S, Maugeri A, et al. Prevalence and Hospital Admissions in Patients with Osteogenesis Imperfecta in the Netherlands: A Nationwide Registry Study. Frontiers in Endocrinology (Lausanne). 2022; 13: 1-7.

Rauch F, Travers R, Parfitt A, and Glorieux F. Static and Dynamic Bone Histomorphometry in Children with Osteogenesis Imperfecta. Bone. 2000; 26(6): 581-589.

Dwan K, Phillipi CA, Steiner RD, and Basel D. Bisphosphonate Therapy for Osteogenesis Imperfecta. Cochrane Database of Systematic Reviews. 2016; 2016: 1-58.

Ruggiero A, Triarico S, Romano A, Maurizi P, Attina G, and Mastrangelo S. Bisphosphonates: From Pharmacology to Treatment. Biomedical &Pharmacology Journal. 2023; 16(1): 221-229.

Hastopraja R and Nasution MS. Osteogenesis Imperfecta: A Case Report. Journal of Endocrinology, Tropical Medicine, and Infectious Disease. 2022; 4(2): 50-55.

Perea SH and Green DW. Osteogenesis Imperfecta: Treatment and Surgical Management. Current Opinion in Pediatrics. 2021; 33(1): 74-78.

Harrington J, Sochett E, and Howard A. Update on the Evaluation and Treatment of Osteogenesis Imperfecta. Pediatric Clinics of North America. 2014; 61(6): 1243-1257.

Cho TJ, Ko JM, Kim H, Shin HI, Yoo WJ, and Shin CH. Management of Osteogenesis Imperfecta: A Multidisciplinary Comprehensive Approach. Clinics of Orthopedic Surgery. 2020; 12(4): 417-429.






Research Article